DEFB109D

Across TCGA pan-cancer cohorts, DEFB109D RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of DEFB109D’s most consistent transcriptional readouts.

The strongest signal is observed in cholangiocarcinoma (CHOL), where DEFB109D RNA is more highly expressed in tumor relative to normal tissue. In most cancer types DEFB109D is over-expressed in tumor, although a few such as BRCA show the opposite, repressed pattern.

CHOL, BRCA, and LIHC are the cancer types where DEFB109D tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DEFB109D RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CHOL	All	All	+1.495	<.001	5	view →
BRCA	Female	All	−0.354	.002	4	view →
LIHC	All	II,III,IV	+0.198	.013	3	view →
LUSC	Female	III,IV	+0.295	.030	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

DEFB109D–CHOL

Open the CHOL breakdown →